Filana Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Filana Therapeutics, Inc. is a clinical‑stage biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system disorders, including tuberous sclerosis complex (TSC)–related epilepsy, and other diseases associated with filamin A dysregulation. The company aims to address unmet medical needs by advancing its lead candidate simufilam, a proprietary small molecule oral therapy, through late‑stage development; it is also pursuing diagnostic and biomarker programs such as SavaDx to detect Alzheimer's disease. Filana Therapeutics operates from its headquarters in Austin, Texas, and has ongoing research and development collaborations and clinical activities aimed at expanding its portfolio and validating filamin A–targeted approaches across CNS indications. Founded in 1998, the company previously operated under a different corporate name and branding and recently rebranded to reflect its strategic emphasis on filamin A–related therapeutics and CNS disease modulation. Filana Therapeutics’ product and service scope includes: development of small molecule therapies targeting filamin A; clinical trial management and execution; biomarker and diagnostic asset development; strategic partnerships and collaborations for drug development, regulatory submission support, and translational research; and ongoing monitoring of regulatory interactions, including responses to agency inquiries, to advance its clinical programs and optimize capital efficiency. The company’s geographic footprint centers on the United States with R&D activities and trials conducted via affiliated sites and collaborations, supported by a network of scientific and clinical advisors and partner organizations to advance its CNS disorder pipeline. Filana Therapeutics’ business segments span therapeutic development, diagnostic asset exploration, and corporate partnerships, with a primary emphasis on CNS diseases tied to filamin A biology.
Company News
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
Zevra Therapeutics (NASDAQ:ZVRA) versus Cassava Sciences (NASDAQ:FLNA) Head-To-Head Contrast